The highly accessible lyophilized mRNA-LNP new crown vaccine shows good stability and immunogenicity in preclinical studies

Jiangsu Ruike Biotechnology Co.
, Ltd.
(“Ricoke Bio”), which is dedicated to the development of innovative vaccines for major diseases, recently announced that its subsidiary Wuhan Ruikeji Biotechnology Co.
, Ltd.
Preclinical data on dosage form mRNA COVID-19 vaccine
.
The lyophilized mRNA-LNP COVID-19 vaccine of Ruikeji Bio uses the LNP delivery system, and the self-developed freeze-drying technology achieves formulation stability at 4 degrees and 25 degrees
.
The vaccine can be stored and transported under conventional cold chain conditions, which greatly improves the accessibility of the vaccine
.
The research results have been published online on bioRxiv
.
According to the paper, Rikage Biotech has developed lyophilized mRNA-LNP vaccines against COVID-19 of the prototype strain, Delta strain and Omicron strain respectively.
The data show that the freeze-drying process does not affect the key physical and chemical indicators, biological activities and immunogens of the vaccine.
sex
.
Notably, the Delta strain lyophilized mRNA-LNP COVID-19 vaccine induced high levels of neutralizing antibodies against the prototype strain and the current major global strain Omicron in mice
.
In the hACE2 transgenic mouse challenge assay, two doses of immunization 14 days apart provided complete protection against challenge with the Delta strain
.
The new crown epidemic has ravaged the world for more than two years, and new mutant strains are constantly emerging
.
In response to the epidemic, vaccines have become one of the most cost-effective means that countries rely on
.
Up to now, more than 10 billion doses of the new crown vaccine have been administered worldwide, but the vaccination rate of at least one dose in low-income countries is only about 10%
.
Improving the pertinence and accessibility of vaccines requires not only the concerted efforts of countries around the world, but also the development of a new generation of safe and effective new crown vaccines that can be stably stored and transported under conventional cold chain or even de-cold chain conditions
.
Ruike Biotech has developed a freeze-dried dosage form of mRNA-LNP new crown vaccine through its subsidiary Ruikeji Biological, which will well meet such needs
.
About Ruike Bio Ruike Bio is an innovative vaccine company founded in 2011.
With the mission and vision of "creating first-class vaccines and protecting human health", it has established three advanced technologies of new adjuvants, protein engineering and immune evaluation.
The platform has a high-value product pipeline portfolio represented by HPV series vaccines, recombinant new crown vaccines, recombinant herpes zoster vaccines, recombinant quadrivalent influenza vaccines, and recombinant adult tuberculosis vaccines.
The core team has more than 20 years of experience
.
About Ruikeji Biology Ruikeji Biology was established in 2021 and is a holding subsidiary of Ruikeji Biology
.
Ruikeji Bio is a biotechnology company with the world's leading mRNA vaccine platform technology and novel adjuvant technology
.
The company is a joint venture established by Jiangsu Ruike Biotechnology Co.
, Ltd.
and Shenzhen Ruiji Biotechnology Co.
, Ltd.
, headquartered in Wuhan
.
The advanced and original technologies possessed by the two parent companies are integrated in Ricogi Bio, with complementary advantages
.
Adhering to the strategy of "embracing the central dogma in immunology", Rikage Bio has independently developed the platform-based technologies required for the design, synthesis and evaluation of mRNA vaccines, and has applied such technologies to the development of various infectious disease vaccines, which is a huge undertaking.
Market prospects and areas of clinical value
.